Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ophthotech

- PMLiVE

Chugai gains FDA breakthrough status for rare CNS treatment

Adds to company's BTD roll-call

- PMLiVE

Roche gains EU PRIME status for Spinraza rival

Oral treatment joins Novartis' gene therapy challenger

- PMLiVE

Novartis withdraws EU filing for canakinumab

Further setback for cardiovascular blockbuster potential

- PMLiVE

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

The majority of patients on Tremfya achieved at least a 90% improvement from PASI score

- PMLiVE

Roche’s O’Day swaps big pharma for big biotech

Move to Gilead enforces reshuffle at neighbours Genentech

- PMLiVE

New models of NHS care – new models of pharma response?

At PME and IQVIA’s roundtable event, leaders discuss how industry needs to adapt to help an NHS undergoing transformational change

- PMLiVE

FDA fast tracks Novartis’ SMA gene therapy

Gene therapy could be approved in first half of 2019, will challenge Biogen's Spinraza

- PMLiVE

Bayer axes 1,250 pharma jobs, with R&D taking the brunt

Part of massive layoff of 12,000 people across conglomerate

- PMLiVE

Novartis to relocate UK headquarters to London’s White City

Emerging life sciences hub has already attracted Autolus

Bayer symbol

Loxo, Bayer get FDA okay for biomarker-driven cancer drug

A first for Loxo, and a second mutation-based targeted drug

- PMLiVE

Novartis gets EU nod for Luxturna gene therapy

Approval comes almost a year after it was secured a green light in the US

Roche Basel Switzerland

Roche builds on Immunocore ImmTAC deal

Extends partnership to target MAGE-A4 protein tumours

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links